Molecule to Market: Inside the outsourcing space

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Pep Gubau, CEO, CTO & Co-Founder at Aizon.

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Pep, covering:

 

How working out what not to do very early on led to two successful growth and exit stories.

Why surrounding yourself with smarter people is essential to learning, scaling, and long term success.

How the industry’s underuse of data led to the creation of Aizon, and the challenge of pitching AI back in 2014 when it was anything but fashionable.

The critical difference between pharma people building technology versus technology companies trying to do pharma.

How pharma and CDMO manufacturing teams should be thinking about digitisation, AI, and transformative technology in a practical, value driven way.

 

Pep Gubau is the CEO and co-founder of Aizon, and a seasoned tech entrepreneur with four decades of experience and two previously successful companies.

He has a unique background as an economist with a foundation in engineering, and he holds several international patents in encryption, data transmission, storage, and processing for regulated cloud environments.

 

Pep is also a frequent speaker on the impact of Big Data, Machine Learning, and other Artificial Intelligence technologies, sharing insights into how these innovations are transforming regulated industries.

 

Molecule to Market is also sponsored by Bora Pharmaceuticals, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with 20+ CEO/c-suite leaders from the CDMO space, who discuss the big headwinds for the pharmaceutical and biotechnology space for 2026.

 

Show features:

Christiane Bardroff, Chief Operating Officer (COO) at Rentschler Biopharma SE

Philip Macnabb, Chief Executive Officer at Curia

Kaan-Fabian Kekec, Partner at Simon-Kucher‘s Healthcare & Life Sciences division

Dirk T. Lange , Chief Executive Officer at Pyramid Pharma Services Bruce Thompson, CTO at Kincell Bio

Bill Vincent, Biotech Entrepreneur, CEO, Board Member

Derek Hennecke - founder, investor, board member

Matthew Bio, CSO at Cambrex & President, Snapdragon Chemistry Stephen Dilly, CEO at Sonoma Biotherapeutics,

Stephen Dilly, CEO at Sonoma Biotherapeutics,

Bill Humphries, Chief Executive Officer at Medpharm

Elisabeth Stampa, CEO at Medichem SL

Kerstin Dolph, SVP of Manufacturing at Charles River Labs

Eric Edwards, Chief Executive Officer at Phlow-USA

Peter DeYoung, CEO at Piramal Pharma

Ian Tzeng, Managing Director at L.E.K. Consulting

Adam Siebert, Managing Director at L.E.K. Consulting

J.D. Mowery, President CDMO Division Bora Pharmaceuticals

Peter Belden President, US, Tjoapack

Nick Fortin, CEO CODIS

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with three senior leaders that attended The JPM's Annual Healthcare Conference 2026:

Chris Garabedian, CEO, Xontogeny and Portfolio Manager, PXV Fund

Dean McAlister, Executive Vice President, Inizio Biotech

Catherine Hunter, Head of Business Development at  ramarketing

 

Hear from experts who have seen multiple cycles and know the difference between noise and signal.We talk real confidence levels, what actually dominated conversations in San Francisco, where capital and opportunity are genuinely moving.

Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with 20+ CEO/c-suite leaders from the CDMO space, who discuss the optimism levels for the pharmaceutical and biotechnology space for 2026.

 

Guests include:

Christiane Bardroff, Chief Operating Officer (COO) at Rentschler Biopharma SE

Philip Macnabb, Chief Executive Officer at Curia

Kaan-Fabian Kekec, Partner at Simon-Kucher‘s Healthcare & Life Sciences division

Dirk T. Lange , Chief Executive Officer at Pyramid Pharma Services Bruce Thompson, CTO at Kincell Bio

Bill Vincent, Biotech Entrepreneur, CEO, Board Member

Derek Hennecke - founder, investor, board member

Matthew Bio, CSO at Cambrex & President, Snapdragon Chemistry Stephen Dilly, CEO at Sonoma Biotherapeutics,

Bill Humphries, Chief Executive Officer at Medpharm

Elisabeth Stampa, CEO at Medichem SL

Philip Lee, CEO at GeneFab

Kerstin Dolph, SVP of Manufacturing at Charles River Labs

Eric Edwards, Chief Executive Officer at Phlow-USA

Peter DeYoung, CEO at Piramal Pharma

Ian Tzeng, Managing Director at L.E.K. Consulting

Adam Siebert, Managing Director at L.E.K. Consulting

J.D. Mowery, President CDMO Division Bora Pharmaceuticals

Peter Belden President, US, Tjoapack

 

Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Selin Kurnaz,  Co-Founder and CEO at Massive Bio,

 

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Selin, covering:

 

How a cancer diagnosis in her family led Selin down a path of accidental entrepreneurship, fundraising, and the application of AI in drug development.

The major pivots in Massive Bio’s journey that transformed it into a broker of access between patients and pharmaceutical companies.

Her views on the misallocation of capital in market access enablers versus research and development.

How gaining traction with advocates inside big pharma helped ensure investors took notice.

Why the influence of AI on clinical trials and real world evidence will continue to grow as part of the patient journey.

 

Selin Kurnaz graduated from Boğaziçi University in Turkey, where she had a dual major in industrial engineering and mechanical engineering. She then continued her education in the United States, where she obtained two masters degrees and a doctorate in mechanical engineering at the University of Michigan. Following her education, Selin served as an executive consultant on strategy, operations, and company trading for a decade. In 2015, she co-founded Massive Bio.

 

 

Molecule to Market is also sponsored by Bora Pharmaceuticals and Charles River Laboratories, and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!